100A
Venture capital firm investing in high-growth technology companies.
13books Capital
13books Capital, formerly Element Ventures, focuses on backing bold founders transforming the financial technology landscape. They are specialists, partnering with Europe's best fintech founders who have global ambitions. The firm emphasizes building lasting relationships with founders, recognizing that meaningful change takes time. Their investment strategy revolves around identifying and supporting companies that are innovating in the way the world thinks about money. While the website doesn't explicitly state the size of fund or AUM, the focus on fintech startups across various stages suggests a strategy aimed at long-term growth and impact in the sector.
20VC
20VC operates at the intersection of venture capital and media, providing deep-dive analysis, interviews, and commentary on tech industry trends, startup news, and venture capital developments through podcasts and articles. It does not invest in startups but serves as a platform for education and discussion within the venture ecosystem.
24 Haymarket
24Haymarket focuses on growth equity and venture capital investments in the UK. They invest aligned private capital to accelerate commercial success. They follow a strict investment thesis with a focus on verticals in the nascent stages of high growth where they can leverage proprietary insight from their Investor Network. The firm focuses on investing in companies that have demonstrated initial commercial traction. They adhere to an active investment philosophy with a right to a board seat in each investment they pursue combined with an involved post-investment model. Their Investor Network is a key differentiator. The firm seeks to leverage the experience and insight of its network members to identify and support promising companies. They aim to complete deals within 6 weeks of the first conversation. 24Haymarket seeks to optimize each investment through connectivity, alignment, transparency, and partnership. They have a collective entrepreneurial, investment and operational experience of over 3,000 years and invest alongside syndicate members' own capital.
3i Group
3i Group is an investment company specializing in Private Equity and Infrastructure. They generate attractive returns for shareholders and co-investors by investing in these asset classes. They take a long-term, responsible approach, aiming to drive sustainable growth in their investee companies. 3i's Private Equity business is funded principally from their own capital, focusing on generating attractive capital returns. Their Infrastructure business manages assets on behalf of third-party investors and 3iās proprietary capital, aiming to generate capital returns while earning fund management fees and portfolio income. The firm adopts a thematic approach to origination and portfolio construction, backing businesses benefiting from structural trends that support long-term sustainable growth. 3i's business model focuses on compounding value by investing in mid-market companies with strong growth potential. They minimize the dilution of capital returns by covering operating costs with income from the portfolio and fund management fees generated by their Infrastructure business. Their proprietary capital allows for a medium to long-term investment horizon, enabling them to compound their capital value through conviction in their best investments. Careful portfolio construction, focusing on resilience across market cycles and targeting sectors and regions with deep expertise, strong networks, and a proven track record are important to the firm. The strategy is adaptable to market shifts, regulatory changes, and broader societal and environmental trends. Investment opportunities are screened against their Responsible Investment policy, and sustainability risks and opportunities are assessed throughout the investment and portfolio management processes. The company has been a signatory to the UN Principles of Responsible Investment since 2011.
4BIO Capital
4BIO Capital is a London-based venture capital firm focused solely on the advanced therapies sector. Their objective is to invest in, support, and grow early-stage companies developing treatments in areas of high unmet medical need. The firm aims to ensure access to these potentially curative therapies for all patients. They target viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The firm offers investors undiluted access to the fastest-growing field of medicine, and to companies, they provide the capital and expert guidance needed to succeed. 4BIO believes in a future where advanced therapies are the standard of care, and they are passionate about using the knowledge and experience of its team to help address the challenge of chronic disease. The team aims to identify companies that are likely to have a real impact on patients' lives. 4BIO's team comprises leading advanced therapy scientists and experienced life science investors. The team members have published over 250 scientific articles in prestigious academic journals, including Nature, The Lancet, Cell, and the New England Journal of Medicine. This deep scientific and investment expertise provides 4BIO with an unrivaled network within the advanced therapy sector and a unique understanding of the criteria that separate the very best investment opportunities. In-depth understanding is the key to success in the rapidly developing therapeutic landscape.
88mph
Venture capital firm investing in high-growth technology companies.
9900 Capital
Based on the available information, BNVT Capital is a venture capital firm that focuses on investing in startups tackling significant societal problems. The firm launched a $150 million debut fund aimed at supporting companies that address these challenges. They seem to be particularly interested in startups and scale-ups. They invest in companies that align with specific impact goals, and focus on specific technology areas to tackle these big challenges.
ALSA Ventures
ALSA Ventures is a London-based international life science investor focused on novel therapeutics. They believe that European innovation in life sciences has the power to create valuable businesses with global impact, coupled with a promising investment market opportunity in Europe. The firm is focused on being a Europe-focused biotechnology fund manager. Their investment approach centers around therapeutics, seeking novel drugs and modalities across a wide variety of disease areas. ALSA Ventures invests across the entire spectrum of drug development, demonstrating comfort in both company formation and participating in syndicates alongside co-investors. The firm aims to build ambitious science-led companies and NewCos around differentiated assets, requiring a wide aperture for talent and ideas, disciplined decision-making, and an ecosystem that allocates capital efficiently. This aligns with their decision to join the Investing in Women Code, which encourages measurable improvements in access to finance and strengthens data-driven accountability across the investment landscape. ALSA Ventures aims to make their engagement with founders consistent, professional, and transparent, which involves clear routes to initial evaluation and feedback, disciplined processes designed to reduce avoidable friction, and a commitment to ongoing review of how their practices affect access to capital.
AP Ventures
AP Ventures is a venture capital firm headquartered in London that focuses on investing in companies driving decarbonisation, with a particular emphasis on hydrogen and its role in transforming the energy and industrial sectors. Since 2013, the firm has been strategically investing in technologies across the hydrogen value chain, recognizing its potential to facilitate the global transition towards sustainable energy solutions. Their investments span hydrogen production, storage, and transportation, as well as innovative hydrogen applications designed to address the structural challenges in industries like mining, transportation, and heavy industry. The firm is committed to advancing and pioneering innovation in hydrogen and decarbonization. AP Ventures also supports carbon capture and extraction technologies as essential components of decarbonisation and the broader energy transition. The firm targets early-stage technology companies with highly differentiated solutions and a global outlook, aligning with the UN Sustainable Development Goals. They actively seek out ventures operating across the entire hydrogen value chain, from the initial production stages to efficient transportation methods and end-use applications. Their investment approach is underpinned by a belief that hydrogen is a critical element in achieving a sustainable energy future. AP Ventures leverages the expertise of a diverse and multidisciplinary team with extensive experience in both industry and finance. The firm benefits from the support of financial and strategic investors who bring significant industrial presence in the energy, mining, and automotive sectors, further solidifying their commitment to the hydrogen value chain and decarbonisation efforts. This collaborative network enhances their ability to identify and nurture promising technologies and businesses that contribute to a cleaner, more sustainable future.
AVIVA Impact Investing
Aviva Investors is a global asset management business of Aviva plc, delivering investment management solutions, services, and client-driven performance to clients worldwide. Their approach is rooted in collaboration, responsible action, and commitment, aiming to design solutions that last. The firm focuses on both public and private markets, offering a range of investment strategies and capabilities tailored for institutional and intermediary investors. Aviva Investors is committed to innovation and technological advancements that can bring positive change, as evidenced by their recent efforts to tokenise traditional fund structures. They are also focused on expanding their reach and impact through strategic investments in key sectors like renewable energy and real estate, as well as strengthening client relationships and distribution capabilities across different geographies. Aviva Investors is actively investing in climate transition strategies, seeking opportunities in core energy markets and new technologies that help industries prepare for the future. A key example is their investment in Terra One Climate Solutions to support the development of battery energy storage systems (BESS) in Germany. This investment reflects their broader strategy of increasing exposure to the renewable energy sector while capturing growth and returns. Additionally, their real estate investments, such as the acquisition of New Broad Street House, align with the strategic priorities of cities like London, aiming to deliver additional office floorspace and unlock development potential. The firm's investment strategy also emphasizes the importance of client service and relationship management, particularly with institutional investors and consultants. They aim to understand the needs of these investors and provide support in navigating market challenges to reach their long-term investment objectives. The appointment of key personnel, such as Heads of EMEA Institutional Client Relationship Management and Global Consultant Relations, underscores their commitment to strengthening these relationships and driving business growth. Aviva Investors also demonstrates a forward-thinking approach by exploring tokenization of fund structures to enhance time and cost efficiency for investors.
Active Partners
Based on the provided text, it is impossible to create a profile for 'Active Partners' as the content describes a domain name sales platform called Yolk.co.uk. There is no information about a venture capital firm named Active Partners, its investment history, philosophy, or geographic strategy. The text focuses on domain sales, transfers, and customer reviews for Yolk.co.uk.
Ada Ventures
Ada Ventures focuses on pre-seed investments in European founders building businesses for a better human future. They aim to find and fund the "Ada Lovelaces of today," prioritizing founder qualities over traditional metrics like CV, past work experience, or gut feel. The firm is committed to inclusive VC, seeking out founders who may be overlooked by more conventional investors due to their backgrounds or networks. They lead >70% of investments and integrate impact assessment into every investment decision. Their AI-Powered Pitch Deck Analysis tool, "Deck Genius", also demonstrates a commitment to supporting founders.
Additio Investment Group
Venture capital firm investing in high-growth technology companies.
Adoreum Partners
Adoreum focuses on the 'chemistry of connection,' emphasizing exhilaration, inspiration, and collaboration between entrepreneurs and investors. Their approach centers on entrepreneurialism, empowerment, compassion, possibility, and delight in fostering meaningful partnerships.
Advance Global Capital
Advance Global Capital (AGC) bridges the financing gap for SMEs in emerging markets by leveraging receivables financing and partnerships with local non-bank financial institutions (NBFIs). The firm prioritizes equitable access to capital, gender-inclusive growth, and alignment with UN Sustainability Goals (5, 8, 9, 10) to foster resilient local economies.
Advent Life Sciences
Advent Life Sciences is a trans-Atlantic venture investor focused on building innovative life sciences businesses in the UK, Europe, and the USA. They aim to turn breakthrough science into approved medicines or medical products. The firm invests in early and mid-stage companies with a first-in-class or best-in-class approach, focusing on new drug discovery across all modalities, med tech, enabling technologies, and vaccines. Advent Life Sciences emphasizes a hands-on approach, working in close alignment and partnership with management teams to realize their vision and achieve superior financial returns by bringing innovation to patients. Advent Life Sciences focuses on understanding the essence of innovation, its competitive relevance, and the most meaningful value-creation steps. They prioritize open communication with founders and executives, sharing diligence and insights to refine business and operating plans. Key elements of company building include agreeing on the scientific and clinical approach, the matching operating plan, team development, syndication, and financing strategy. The firm emphasizes loyalty and pragmatic partnership throughout a company's journey. They aim to be constructively critical while remaining patient, supportive, and aligned in their aims. They focus on exceptional innovation early, with initial investments often at the Seed stage or Series A.
Aer Venture Studios
Venture capital firm investing in high-growth technology companies.
Agronomics
Agronomics focuses on investing in companies that are addressing inefficiencies in the global food production system by pioneering new methods that require fewer resources and generate less waste. They believe that conventional agriculture is not only unsustainable but also financially unviable. Their investment strategy targets companies in the cellular agriculture sector, covering various areas like cultivated meat (beef, pork, chicken), egg proteins, dairy, palm oil, cocoa, cotton, leather, and fermentation commercialization. They aim to provide individual investors access to clean agriculture companies through a single, publicly traded stock. For institutional investors, they offer strategic exposure to innovative food tech companies that are solving food security challenges and creating local jobs, while aligning with ESG mandates and climate-focused allocations. Agronomics actively seeks companies positioned to transform the $10 trillion conventional food production market with more efficient alternatives. The firm highlights the instability and inefficiency caused by modern agriculture's reliance on complex, fragile supply chains, which are susceptible to geopolitical tensions, zoonotic diseases, and climate change. They point to statistics such as the increase in wheat and egg prices, and supply chain disruptions to underscore the urgency for alternative solutions. Agronomics positions its portfolio companies as key players in addressing these challenges and creating a more sustainable and resilient food system. Agronomics invests in companies utilizing technologies such as precision fermentation, synthetic biology, and gene editing to create alternative protein sources, improve crop yields, and produce green hydrogen. They also support companies developing pet food and other materials using these technologies. By investing in companies at different stages, they aim to contribute to the transformation of the food industry and create value for their investors.
Ahren Capital
MarkUpgrade believes strategic-grade domain names save businesses time, money, and energy while unlocking growth, clarity, and trust.
Alba Equity
Venture capital firm investing in high-growth technology companies.
Alis Biosciences
Venture capital firm investing in high-growth technology companies.
Alpha Star Capital
Alpha Star Capital focuses on partnering with avant-garde entrepreneurs, acting as lead and anchor investors for the long term. They emphasize a different pace and a deeper commitment, choosing the long view in a world accelerating through disruption. They believe lasting value emerges from bold exploration, enduring relationships, and continuous care, supporting both strategy and execution. They aim to be actively involved in society's foundational shifts where art, science, and technology intersect.
Amadeus APEX Technology Fund
Amadeus Capital Partners is a deep tech venture capital firm that invests from seed to growth stages. Since 1997, they have backed over 200 companies and raised over $1.3 billion for investment. Their investment strategy focuses on solving hard problems in large markets within three core technology areas: Intelligence (AI, advanced computing, and quantum), Human (health, medicine, and wellness), and Planet (sustainability, energy, novel materials, and space utilization). The firm aims to create value by supporting trailblazing companies in these sectors. The firm emphasizes a long-term perspective, as demonstrated by their investments in companies like OrganOx, where they saw a 14-year journey from initial investment by The Royal Society to its acquisition by Terumo for $1.5 billion. This commitment to nurturing companies over the long term suggests a patient capital approach. The firm actively seeks opportunities in European Deep Tech through a partnership with APEX Ventures, highlighted by the Amadeus APEX Technology Fund, which invests in areas like space technology. Amadeus Capital Partners has a track record of successful exits, including the acquisitions of OrganOx, Ravelin, and Cryptosense. These exits validate their investment thesis and demonstrate their ability to identify and support companies with strong growth potential. Their investment in Sitehop, a leader in post-quantum cryptography, underscores their focus on emerging technologies and their willingness to invest in early-stage ventures with significant market opportunities. By focusing on deep tech areas aligned with Intelligence, Human, and Planet, Amadeus Capital Partners positions itself to capitalize on the transformative potential of these technologies. The firm's experience, extensive network, and proven track record make it a valuable partner for entrepreneurs seeking to build innovative and impactful companies.